Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model

Cancer Biology and Therapy

Volumn 8, Issue 20, 2009, Pages 1940-1946

  Yang, Kwang Mo ^a,b   Russell, James ^a   Lupu, Mihaela E ^a   Cho, HyungJoon ^a   Li, Xiao Feng ^a,c   Koutcher, Jason A ^a   Ling, C Clifton ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Korean Institute of Radiological and Medical Sciences   (South Korea)

^c University of Louisville School of Medicine   (United States)

Author keywords

Atrasentan; EF5; HT29; Pimonidazole; Tumor hypoxia; Tumor perfusion

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; ATRASENTAN; GADOLINIUM PENTETATE; PIMONIDAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; QUANTITATIVE ANALYSIS; RADIATION INJURY; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANOXIA; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; ETANIDAZOLE; GADOLINIUM DTPA; HT29 CELLS; HUMANS; HYDROCARBONS, FLUORINATED; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, NUDE; NITROIMIDAZOLES; PERFUSION; PYRROLIDINES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73549109169     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.20.9595     Document Type: Article

References (39)

1. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3:110-6.
2. Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 2007; 47:731-59.
3. Hayasaki Y, Nakajima M, Kitano Y, Iwasaki T, Shimamura T, Iwaki K. ICAM-1 expression on cardiac myocytes and aortic endothelial cells via their specific endothelin receptor subtype. Biochem Biophys Res Commun 1996; 229:817-24.
4. Kallakuri S, Kreipke CW, Rossi N, Rafols JA, Petrov T. Spatial alterations in endothelin receptor expression are temporally associated with the altered microcirculation after brain trauma. Neurol Res 2007; 29:362-8.
5. Yokomori H, Oda M, Ogi M, Kamegaya Y, Tsukada N, Nakamura M, Ishii H. Enhanced expression of endothelin receptor subtypes in cirrhotic rat liver. Liver 2001; 21:114-22.
6. Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB, et al. Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer 2001; 85:1759-63.
7. A in human papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2003; 59:354-60.
8. Ali H, Loizidou M, Dashwood M, Savage F, Sheard C, Taylor I. Stimulation of colorectal cancer cell line growth by ET-1 and its inhibition by ET(A) antagonists. Gut 2000; 47:685-8.
9. Berry PA, Zhang YF, Carter ND, Jeffery S, Burchill SA. Decreased wild-type full-length Et-A and -B receptors in neuroblastoma and Ewing sarcoma cells. Med Pediatr Oncol 2001; 36:142-6.
10. B ET receptors by the prostatic epithelium and stroma. J Clin Endocrinol Metab 1997; 82:508-13.
11. Pflug BR, Zheng H, Udan MS, D'Antonio JM, Marshall FF, Brooks JD, Nelson JB. Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett 2007; 246:139-48.
12. Nelson JB, Udan MS, Guruli G, Pflug BR. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 2005; 7:631-7.
13. Wu-Wong JR, Chiou WJ, Wang J. Extracellular signal-regulated kinases are involved in the antiapoptotic effect of endothelin-1. J Pharmacol Exp Ther 2000; 293:514-21.
14. Del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosano L, et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 2002; 61:524-32.
15. A receptor-mediated phenomenon. Br J Pharmacol 1996; 118:191-7.
16. Hafizi S, Allen SP, Goodwin AT, Chester AH, Yacoub MH. Endothelin-1 stimulates proliferation of human coronary smooth muscle cells via the ET(A) receptor and is co-mitogenic with growth factors. Atherosclerosis 1999; 146:351-9.
17. Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008; 14:6270-6.
18. Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, et al. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res 2008; 14:1464-9.
19. Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113:2478-87.
20. Battistini B, Berthiaume N, Kelland NF, Webb DJ, Kohan DE. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood) 2006; 231:653-95.
21. Martinive P, De Wever J, Bouzin C, Baudelet C, Sonveaux P, Grégoire V, et al. Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol Cancer Ther 2006; 5:1620-7.
22. Sonveaux P, Dessy C, Martinive P, Havaux X, Jordan BF, Gallez B, et al. Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res 2004; 64:3209-14.
23. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007; 25:4066-74.
24. Kaanders JH, Bussink J, van der Kogel AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002; 3:728-37.
25. Hulshof MC, Rehmann CJ, Booij J, van Royen EA, Bosch DA, Gonzalez Gonzalez D. Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a 99mTc-HMPAO SPECT study. Radiother Oncol 1998; 48:135-42.
26. Wu-Wong JR, Dixon DB, Chiou WJ, Sorensen BK, Liu G, Jae HS, et al. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies. Clin Sci (Lond) 2002; 103:107-11.
27. Bagnato A, Cirilli A, Salani D, Simeone P, Muller A, Nicotra MR, et al. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 2002; 62:6381-4.
28. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and Taxotere combination in prostate cancer. Cancer Res 2007; 67:3818-26.
29. Vernerova Z, Kramer HJ, Backer A, Cervenka L, Opocensky M, Huskova Z, et al. Late-onset endothelin receptor blockade in hypertensive heterozygous REN-2 transgenic rats. Vascul Pharmacol 2008; 48:165-73.
30. Sachidanandam K, Elgebaly MM, Harris AK, Hutchinson JR, Mezzetti EM, Portik-Dobos V, Ergul A. Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes. Am J Physiol Heart Circ Physiol 2008; 294:2743-9.
31. B blockade. Am J Physiol Heart Circ Physiol 2006; 290:2554-9.
32. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, Nelson PT, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004; 10:8177-84.
33. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002; 62:7066-74.
34. Ljungkvist AS, Bussink J, Rijken PF, Raleigh JA, Denekamp J, Van Der Kogel AJ. Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys 2000; 48:1529-38.
35. Russell J, Carlin S, Burke SA, Wen B, Yang KM, Ling CC. Immunohistochemical detection of changes in tumor hypoxia. Int J Radiat Oncol Biol Phys 2009; 73:1177-86.
36. A-selective receptor antagonist. J Pharmacol Exp Ther 1996; 276:473-81.
37. A selective endothelin antagonist, in humans. Br J Clin Pharmacol 2000; 49:562-73.
38. Guichard M, Dertinger H, Malaise EP. Radiosensitivity of four human tumor xenografts. Influence of hypoxia and cell-cell contact. Radiat Res 1983; 95:602-9.
39. Hoffmann U, Brix G, Knopp MV, Hess T, Lorenz WJ. Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 1995; 33:506-14.